pharmaphorum Podcast

Technology and AI can help healthcare systems tackle the affordability challenge while ensuring patients still benefit from cutting-edge treatments.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Alfred Olivares, global managing partner, healthcare & medtech, at HTEC, in a conversation addressing how innovation can reach patients in a financially sustainable way.

Olivares discusses digital transformation t...

There are many efforts at the moment to transform the expensive, labour intensive, and high failure rate processes of drug discovery into automated drug design.

And Simon Kohl, founder and CEO of Latent Labs, knows this intimately. In a new episode of the pharmaphorum podcast, Kohl discusses Latent Labs’ emergence from stealth, as well as protein design and drug discovery acceleration in more detail, as well as the importance of de...

A CDMO plays a crucial role in the pharmaceutical and biotechnology industries by providing comprehensive drug development and manufacturing services, enabling companies to efficiently bring new medicines to market.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Sigma Mostafa, CSO at KBI BioPharma, about the role of CDMOs and the important factors companies should consider when selecting one.

Mostafa sets out ...

Drug shortages are a critical issue in the US, leaving patients and healthcare providers struggling. Compounding pharmacies, however, can curb drug shortages and help lessen this growing threat to the public's health. 

In a  new pharmaphorum podcast, web editor Nicole Raleigh speaks with Shawn Hodges, CEO of Revelation Pharma, a nationwide network of 503A and 503B compounding pharmacies, spanning across various locations.

Hodges di...

Intra-tumourally injected therapeutics represent a novel approach to cancer cell death, with high tumour dispersion and cell penetration properties.

To discuss the potential of these therapeutics to kill tumours and elicit an adaptive immune response within mere days of injection, pharmaphorum spoke with Lew Bender, CEO of Intensity Therapeutics Inc.

Bender discusses the possibility of shifting the oncological treatment paradigm wi...

There is a growing body of evidence on the role of inflammation in predicting heart health.

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Sandeep Kulkarni, CEO of Tourmaline Bio, about addressing inflammation, and also the impact of AI and GLP-1s on cardiology clinical trials and drug development.

Kulkarni also discusses Tourmaline’s IL-6 inhibitor for atherosclerotic cardiovascular disease, and his hopes for ...

With over 7,000 rare diseases affecting an estimated 30 million people in the US alone, these conditions have long been underfunded and under-researched, leaving patients with limited options. However, virtual trials are emerging as a breakthrough. 

In a new pharmaphorum podcast, web editor Nicole Raleigh is joined by Piet van der Graaf, Senior VP at Certara – a company providing predictive simulation, data-driven modelling, and AI...

Graphite Digital’s study of 100 senior pharma leaders across Europe and North America earlier this year investigated organisations’ attitudes towards hot industry topics, including – of course – AI, omnichannel, and globalisation.

So it was pharmaphorum web editor Nicole Raleigh welcomed Graphite Digital’s CEO, Rob Verheul, to the podcast as guest, in order to discuss digital strategy and the Salesforce-Veeva split.

Verheul also co...

Last week in Berlin the Frontiers Health Conference celebrated its 10th Anniversary with a whirlwind two days of panels and presentations from founders, executives, and patients across the healthcare ecosystem.

Whilst there, pharmaphorum editor-in-chief Jonah Comstock and web editor Nicole Raleigh, together with Frontiers Health co-host Jessica DaMassa, met up on-site immediately after the event came to a close in order to discuss ...

Process innovation in the pharmaceutical industry is never easy, but its best chance of success comes when companies come together to work on big problems – especially when they bring in regulators and other stakeholders.

In today’s episode of the pharmaphorum podcast, host Jonah Comstock speaks with Rob DiCicco, vice president of portfolio management at TransCelerate Biopharma, a membership organisation where big pharma companie...

At the end of September, President Trump invited Pfizer CEO Albert Bourla to the Oval Office to announce that the company and the administration had reached a "deal" on most-favoured nations drug pricing. This was followed by similar announcements from AstraZeneca and Merck. But are these deals substantive policy or PR sleight of hand?

In today’s episode of the pharmaphorum podcast, host Jonah Comstock invites Hogan Lovells Partner...

Amid historic advances in cell-based therapies and precision medicine, biotech’s biggest challenge isn’t scientific, it’s political.

In a new pharmaphorum podcast, James Roosevelt Jr, a longtime healthcare leader, former associate commissioner of social security for retirement policy, and grandson of FDR, as well as Advisory Board Member for Pluri Inc, discusses regulatory bottlenecks and their stalling effect on cell-based therapi...

Radiation has for over a century been considered one of the most powerful methods of destroying cancer. But, even now, ways to deliver significant doses to a tumour without damaging normal surrounding tissue are few. And this is where targeted radiotherapeutics come in.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Marc Hedrick, president and CEO of Plus Therapeutics, a clinical stage pharmaceutical compan...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Ilya Burkov, global head of healthcare & life sciences at Nebius, a company building one of the world’s leading AI infrastructure companies.

Burkov discusses the deployment of AI and cloud-native infrastructure for improving the speed and indeed quality of drug development, as well as why access to compute not enough and how GenAI is helping pharma teams integ...

Bayer and Veeva have partnered for several years across commercial, R&D, and quality functions. But recently Bayer migrated to Veeva’s Vault CRM, taking that relationship, and Bayer’s connected platform journey, to the next level.

In order to discuss this migration further, pharmaphorum spoke with Alexander Alex, head of Veeva Platform at Bayer, and Florian Schnappauf, vice president of enterprise commercial strategy at Veeva.

...

As pharmaphorum reported during ESMO 2025, fresh from a return to oncology with the FDA approval of zongertinib as a treatment for HER2-positive non-small cell lung cancer (NSCLC), tumour shrinkage observed by investigator review - Boehringer Ingelheim is racing to expand its label.

As the company reported new data at the Congress from the phase 1b Beamion LUNG-1 study, underpinning the approval of zongertinib (Hernexeos) as a seco...

Back in June, pharmaphorum spoke with Entity Risk’s CEO and co-founder, Neal Masia, a leading health economist, about the unknowns unfolding in the US following the commencement of the second Trump administration this year.

Tune into today’s podcast for an exploration of the potential scenarios Masia mused might arise, as well as his insights on the 340B Program, PBMs, and risk-based contracts.

You can listen to episode 210 of the ...

In the final episode of our special Frontiers Health limited series of the pharmaphorum podcast, web editor Nicole Raleigh speaks with the Chairman of Frontiers Health, Robert Ascione.

Ascione - a serial entrepreneur & thought leader in health innovation and digital health, global executive, CEO and founder of Healthware Group, and President of Health Innovation at EVERSANA – talks about his favourite memory from Frontiers Heal...

As Gain Therapeutics announces positive Phase 1b results for its lead compound, GT-02287, pharmaphorum looks back to a conversation with the company’s CEO Gene Mack earlier in the year, discussing allosteric small molecule therapies in the Parkinson’s disease space.

Mack discusses the company’s progress in this field, and explores where next in terms of the unmet needs of Parkinson’s disease and the potential of this specific area ...